DESTINY-Breast15: T-DXd in patients with HR+HR- and HER2-low or HER2 IHC 0 metastatic breast cancer [Video]

Antonio Llombart-Cussac, MD, PhD, Hospital Arnau de Vilanova, Valencia, Spain, provides an overview of the ongoing Phase III DESTINY-Breast15 trial (NCT05950945) investigating trastuzumab deruxtecan (T-DXd) in patients who have hormone receptor-negative and hormone receptor-positive HER2-low or HER2 IHC 0 metastatic breast cancer. The trial initiated in December 2023, is incorporating a robust biological approach, requiring patients to undergo a biopsy within three to four weeks before inclusion to accurately determine their HER2 status. Additional biopsies will be conducted in both metastatic and early settings, with a follow-up biopsy after two treatment cycles. This extensive approach, coupled with digital pathology and AI intelligence, seeks to understand the HER2 expression pattern and identify potential biomarkers for treatment response. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.